Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc., a developer of new treatments for amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases, has raised $30 million in Series B financing.
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc., a developer of new treatments for amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases, has raised $30 million in Series B financing. Morningside Ventures led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: